Federated Hermes, Inc. Freeline Therapeutics Holdings PLC Transaction History

Federated Hermes, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	BUY	$0.92 - $2.03 $18,400 - $40,599	20,000 Added 50.0%	60,000 $67,000
Q4 2021 Feb 14, 2022	BUY	$1.97 - $3.45 $19,700 - $34,500	10,000 Added 33.33%	40,000 $79,000
Q3 2021 Nov 15, 2021	BUY	$3.04 - $8.9 $54,720 - $160,200	18,000 Added 150.0%	30,000 $103,000
Q2 2021 Aug 16, 2021	SELL	$8.15 - $13.9 $65,200 - $111,200	-8,000 Reduced 40.0%	12,000 $98,000
Q3 2020 Nov 12, 2020	BUY	$15.45 - $18.12 $309,000 - $362,400	20,000 New	20,000 $312,000

30.1K

Ticker FRLN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,972,300
Description
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in P...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.